ATE491474T1 - Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists - Google Patents

Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists

Info

Publication number
ATE491474T1
ATE491474T1 AT01942162T AT01942162T ATE491474T1 AT E491474 T1 ATE491474 T1 AT E491474T1 AT 01942162 T AT01942162 T AT 01942162T AT 01942162 T AT01942162 T AT 01942162T AT E491474 T1 ATE491474 T1 AT E491474T1
Authority
AT
Austria
Prior art keywords
nmda
aspartate
methyl
treatment
receptor antagonist
Prior art date
Application number
AT01942162T
Other languages
English (en)
Inventor
Christine Sang
Original Assignee
Sang Christine Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sang Christine Dr filed Critical Sang Christine Dr
Application granted granted Critical
Publication of ATE491474T1 publication Critical patent/ATE491474T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT01942162T 2001-06-07 2001-06-07 Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists ATE491474T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/018723 WO2002100434A1 (en) 2001-06-07 2001-06-07 Treatment of neuropathic pain with n-methyl-d-aspartate (nmda) receptor antagonists

Publications (1)

Publication Number Publication Date
ATE491474T1 true ATE491474T1 (de) 2011-01-15

Family

ID=21742637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01942162T ATE491474T1 (de) 2001-06-07 2001-06-07 Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists

Country Status (10)

Country Link
US (2) US8309570B2 (de)
EP (3) EP1395289B1 (de)
AT (1) ATE491474T1 (de)
CA (1) CA2449987C (de)
CY (2) CY1111900T1 (de)
DE (1) DE60143671D1 (de)
DK (2) DK2266558T3 (de)
ES (2) ES2357808T3 (de)
PT (1) PT2266558T (de)
WO (1) WO2002100434A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100434A1 (en) 2001-06-07 2002-12-19 The General Hospital Corporation Treatment of neuropathic pain with n-methyl-d-aspartate (nmda) receptor antagonists
FR2980973B1 (fr) * 2011-10-11 2013-11-15 Univ Clermont Auvergne Composition pour le traitement prophylactique de la douleur neuropathique.
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
WO2018229241A1 (en) * 2017-06-16 2018-12-20 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Means and methods for treating neuropathic pain
IL294709B2 (en) * 2020-01-13 2023-07-01 Astromedical Biotechnology Ltd Use of ketamine in the treatment of cachexia

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316888A (en) * 1980-04-15 1982-02-23 Nelson Research & Development Co. Method and composition of reducing pain
US4446140A (en) * 1981-12-10 1984-05-01 Nelson Research & Development Company Method and composition for treating mouth pain
US5629307A (en) * 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US5164398A (en) * 1991-04-01 1992-11-17 Merck & Co., Inc. Ibuprofen-antitussive combinations
US5834479A (en) * 1993-03-05 1998-11-10 Mayer; David J. Method and composition for alleviating pain
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5352683A (en) * 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
JP4097285B2 (ja) * 1994-09-22 2008-06-11 リチャード・アラン・スミス 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
US5840731A (en) * 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
WO1998007447A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US5919826A (en) * 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
US6284794B1 (en) * 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US5801188A (en) * 1997-01-08 1998-09-01 Medtronic Inc. Clonidine therapy enhancement
CA2289190A1 (en) 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
WO1998050075A1 (en) 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with nmda-blockers for treating pain
WO1999007413A1 (en) 1997-08-11 1999-02-18 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
EP1014959B1 (de) 1997-08-15 2004-10-20 Carolyn Ann Fairbanks Agmatin für die behandlung neuropathischer schmerzen
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
FR2772271B1 (fr) * 1997-12-11 2000-09-01 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
US6007841A (en) * 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
AU750822B2 (en) * 1998-04-03 2002-08-01 Triangle Pharmaceuticals, Inc. Systems, methods and computer program products for guiding the selection of therapeutic treatment regimens
US6054451A (en) * 1998-04-21 2000-04-25 Algos Pharmaceutical Corporation Analgesic composition and method for alleviating pain
BR9912827A (pt) 1998-07-16 2001-05-02 Sloan Kettering Inst Cancer Composições tópicas compreendendo um analgésico opióide e um antagonista de nmda
US20010007872A1 (en) * 1998-10-01 2001-07-12 Frank S. Menniti Method of treating acute, chronic and/or neuropathic pain
CA2351224A1 (en) 1998-11-12 2000-05-25 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with nmda-blockers for treating pain
GB9901691D0 (en) 1999-01-26 1999-03-17 Cerebrus Ltd Chemical compounds
AU2319100A (en) * 1999-01-28 2000-08-18 Nippon Shinyaku Co. Ltd. Amide derivatives and drug compositions
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
GB9904163D0 (en) * 1999-02-23 1999-04-14 Bioglan Lab Ltd Pharmaceutical compositions
PT1035115E (pt) * 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP1238069A2 (de) 1999-07-15 2002-09-11 McGill University Antisense oligonucleotiden für mglur1
WO2001008705A1 (en) 1999-08-02 2001-02-08 Yamanouchi Pharmaceutical Co., Ltd. Remedies for neurogenic pains
CN1204139C (zh) * 1999-08-24 2005-06-01 东丽株式会社 神经性疼痛治疗剂
US6677452B1 (en) 1999-09-30 2004-01-13 Lion Bioscience Ag Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof
WO2001062954A2 (en) * 2000-02-24 2001-08-30 Xenon Genetics, Inc. Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
IL152473A0 (en) * 2000-04-28 2003-05-29 Sloan Kettering Inst Cancer Topical anesthetic/opioid formulations and uses thereof
DE60130771T2 (de) * 2000-07-27 2008-07-17 Eli Lilly And Co., Indianapolis Substituierte heterocyclische amide
US7685005B2 (en) * 2000-08-29 2010-03-23 Medtronic, Inc. Medical device systems implemented network scheme for remote patient management
ATE402262T1 (de) 2000-09-26 2008-08-15 Xenon Pharmaceuticals Inc Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden
WO2002100434A1 (en) 2001-06-07 2002-12-19 The General Hospital Corporation Treatment of neuropathic pain with n-methyl-d-aspartate (nmda) receptor antagonists
DE60230266D1 (de) * 2001-06-15 2009-01-22 Astellas Pharma Inc Phenylpyridincarbonyl piperazinderivate
EP1452525A4 (de) * 2001-10-30 2005-01-26 Nippon Shinyaku Co Ltd Amidderivate und arzneimittel
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
US7973064B2 (en) * 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
AU2002350172A1 (en) * 2001-12-07 2003-06-23 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
EP1471909A4 (de) 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc Pharmazeutische zusammensetzung und verfahren zur behandlung von erkrankungen des zentralen nervensystems
AU2003251933A1 (en) * 2002-07-25 2004-02-16 Wisconsin Alumni Research Foundation Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes
WO2004022002A2 (en) * 2002-09-09 2004-03-18 Endo Pharmaceuticals Inc. Combined immediate release and extended release analgesic composition
US7256200B2 (en) * 2003-02-10 2007-08-14 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Method and composition for potentiating an oplate analgesic
WO2004075832A2 (en) * 2003-02-27 2004-09-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
HUP0300929A3 (en) * 2003-04-09 2005-06-28 Richter Gedeon Vegyeszet Analgetic and/or muscle relaxant pharmaceutical composition
EP1613324A2 (de) 2003-04-14 2006-01-11 Pain Therapeutics, Inc. Verfahren zur behandlung von schmerzen mit opioid-antagonisten
US7404970B2 (en) * 2004-04-13 2008-07-29 Konec, Inc. Pain relief composition, method to form same, and method to use same
WO2005102390A2 (en) 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
US20060052370A1 (en) * 2004-08-24 2006-03-09 Meyerson Laurence R Methods and compositions for treating nociceptive pain
US20060240043A1 (en) * 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain

Also Published As

Publication number Publication date
EP2266558A2 (de) 2010-12-29
EP2266558A3 (de) 2011-11-23
US20130123295A1 (en) 2013-05-16
EP1395289B1 (de) 2010-12-15
CY1119257T1 (el) 2018-02-14
EP2266558B1 (de) 2017-04-19
EP2266566A3 (de) 2011-01-12
WO2002100434A1 (en) 2002-12-19
DE60143671D1 (de) 2011-01-27
EP1395289A1 (de) 2004-03-10
US8309570B2 (en) 2012-11-13
CA2449987A1 (en) 2002-12-19
DK2266558T3 (en) 2017-07-31
ES2357808T3 (es) 2011-04-29
CA2449987C (en) 2015-11-03
EP2266566A2 (de) 2010-12-29
DK1395289T3 (da) 2011-03-28
PT2266558T (pt) 2017-07-21
ES2632544T3 (es) 2017-09-14
US20050009916A1 (en) 2005-01-13
CY1111900T1 (el) 2015-11-04

Similar Documents

Publication Publication Date Title
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
TW200518753A (en) Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
MA28008A1 (fr) Derives pyridyle et leur utilisation en tant qu'agents therapeutiques
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
RU2003132687A (ru) Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
DE602005023782D1 (de) Pyrrolidinderivate zur behandlung einer von der reninaktivität abhängigen krankheit
DE60001586D1 (de) Diphenyl-piperidin derivate
CY1119257T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα δεξτρομεθορφανης n-meθυλ-d-ασπαρτικων (nmda)
BR9910899A (pt) Compostos de ácido sulfÈnico ou sulfonilamino n-(hetero-aralquil)-azaeterocicliamida
EP1379508A4 (de) N-(aryl)-2-arylethensulfonamide und ihre therapeutischen anwendungen
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
CA2534634A1 (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
ATE554764T1 (de) Wirkungsvolle vereinfachte derivate von immunosuppressiva

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1395289

Country of ref document: EP